TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20472597

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 508

Group type: COMPARATOR
Intervention: Sequential monotherapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: Step-up combination therapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: Initial combination with prednisone
Number of subjects: 508

Group type: COMPARATOR
Intervention: Initial combination with infliximab
Number of subjects: 508
Study: 18357884

Group type: EXPERIMENTAL
Intervention: 25% AlCl3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 15.5% Fe2(SO4)3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.1% HCl‐epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 40
Study: 15796287

Group type: EXPERIMENTAL
Intervention: Warm air drying while rubbing for 15 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Warm air drying without ultraviolet light while holding hands stationary
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Warm air drying with ultraviolet light
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three sheets of paper towel drying
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Warm air drying while holding hands stationary, paper towels, and warm air drying while rubbing hands
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paper towels
Number of subjects: 30
Study: 12836812

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 31

Group type: COMPARATOR
Intervention: Travoprost 0.004%
Number of subjects: 31
Study: 10374215

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conjugated equine estrogens 0.625 mg/day with norgestrel 0.15 mg/day
Number of subjects: 97
Study: 8911002

Group type: EXPERIMENTAL
Intervention: 720 EL. U of hepatitis A antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1440 EL. U of hepatitis A antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 720 EL. U and 1440 EL. U of hepatitis A antigen
Number of subjects: 0
Study: 1989570

Group type: EXPERIMENTAL
Intervention: Counseling plus six individual sessions of stress prevention training
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Counseling plus a three-session interactive video program
Number of subjects: 1307
Study: 7065478

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (2.5-5.0 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31706187

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 6738

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 6738
Study: 30816637

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg by mouth daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 27348852

Group type: EXPERIMENTAL
Intervention: Duraphat®
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clinpro™ White Varnish
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MI Varnish™
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Embrace™ Varnish
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enamel Pro® Varnish
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no varnish)
Number of subjects: 60
Study: 25837634

Group type: EXPERIMENTAL
Intervention: G‐eCPD module (n = 80)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Live genetic CPD module (n = 88)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Live training
Number of subjects: 168

Group type: COMPARATOR
Intervention: Online oncogenetics training
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Supportive website
Number of subjects: 168
Study: 24229688

Group type: EXPERIMENTAL
Intervention: rhTPO plus CsA
Number of subjects: 36

Group type: COMPARATOR
Intervention: rhTPO alone
Number of subjects: 36
Study: 21304242

Group type: COMPARATOR
Intervention: Control arm of ventilation monitoring during endoscopy
Number of subjects: 123
Study: 19476985

Group type: EXPERIMENTAL
Intervention: Low-dose, slow-release transdermal glyceryl trinitrate (GTN) patch
Number of subjects: 29

Group type: COMPARATOR
Intervention: Matched control group (no immediate treatment for PSA recurrence)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Treatment group (GTN)
Number of subjects: 29
Study: 18177194

Group type: EXPERIMENTAL
Intervention: Cleft lip participants with hyposensitive altered sensations
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cleft lip participants with altered midface sensation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Bilateral cleft lip participants
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cleft lip participants
Number of subjects: 93

Group type: COMPARATOR
Intervention: Noncleft participants
Number of subjects: 93
Study: 14993623

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP) - 25 mg/kg of sulfadoxine and 1.25 mg/kg of pyrimethamine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chloroquine (CQ) - 25 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP)
Number of subjects: 80
Study: 15570192

Group type: EXPERIMENTAL
Intervention: Low dose (10 mg) methamphetamine hydrochloride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High dose (20 mg) methamphetamine hydrochloride
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both doses (10 mg and 20 mg)
Number of subjects: 8
Study: 10597969

Group type: EXPERIMENTAL
Intervention: Maximum hygienic protocol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Limited aseptic precautions
Number of subjects: 200
Study: 7572649

Group type: EXPERIMENTAL
Intervention: Maximal symptom-limited exercise ergometric stress testing (Ex)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Intravenous dipyridamole (0.7 to 0.8 mg/kg) stress testing (Dip)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.7 to 0.8 mg/kg) plus nonlimited exercise stress testing (Dip+Ex)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Dipyridamole (0.7 to 0.8 mg/kg) stress testing (Dip)
Number of subjects: 397
Study: 2149285

Group type: EXPERIMENTAL
Intervention: Toremifene 240 mg daily
Number of subjects: 650

Group type: COMPARATOR
Intervention: Toremifene 60 mg daily
Number of subjects: 650

Group type: COMPARATOR
Intervention: Tamoxifen 20-40 mg daily
Number of subjects: 650
Study: 7015988

Group type: EXPERIMENTAL
Intervention: sotalol (80 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: atenolol (50 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: sotalol + prazosin (3-5 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: atenolol + prazosin (3-5 mg b.i.d.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: prazosin (3-5 mg b.i.d.) alone
Number of subjects: 18
Study: 29605229

Group type: EXPERIMENTAL
Intervention: Successful Soothing Condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Failed Soothing Condition
Number of subjects: 60
Study: 28535546

Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections
Number of subjects: 360
Study: 26084343

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri SD5865
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 25153092

Group type: EXPERIMENTAL
Intervention: Telephone CBT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-to-face CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phone CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22937725

Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with ropivacaine 0.75%
Number of subjects: 108

Group type: COMPARATOR
Intervention: Epidural anesthesia with ropivacaine 0.75%
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 108
Study: 19953810

Group type: EXPERIMENTAL
Intervention: Compomer (Dyract AP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (Fuji IILC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High viscosity glass ionomer cement (Fuji IX)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 45
Study: 17296625

Group type: EXPERIMENTAL
Intervention: Baseline Physical Component Summary (PCS)
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Baseline Mental Component Summary (MCS)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: ICD therapy for ventricular tachyarrhythmias
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: ICD shocks
Number of subjects: 1058
Study: 15073389

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Flickering light
Number of subjects: 38
Study: 12634563

Group type: EXPERIMENTAL
Intervention: Low-grade isthmic spondylolisthesis group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-grade isthmic spondylolisthesis group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pediatric control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adult control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of low-grade and high-grade isthmic spondylolisthesis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation with Meyerding-Newman scores
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall comparison of spondylolisthesis groups with controls
Number of subjects: 40
Study: 9649979

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 50
Study: 7654893

Group type: EXPERIMENTAL
Intervention: SCFA treatment (100 mL, twice daily enemas of sodium acetate 80 mmol/L, sodium propionate 30 mmol/L and sodium butyrate 40 mmol/L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SCFA treatment
Number of subjects: 40
Study: 30878970

Group type: EXPERIMENTAL
Intervention: VIG (70% VO2peak)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: BIKE
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: All exercise groups (BIKE, MOD, VIG)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CON
Number of subjects: 188
Study: 29223437

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Heparin with or without GPI
Number of subjects: 2149
Study: 26173169

Group type: EXPERIMENTAL
Intervention: Algisyl‐LVR
Number of subjects: 11
Study: 23759284

Group type: EXPERIMENTAL
Intervention: Lenient rate control
Number of subjects: 614

Group type: COMPARATOR
Intervention: Strict rate control
Number of subjects: 614
Study: 20660556

Group type: EXPERIMENTAL
Intervention: Health promotion/obesity prevention program (Challenge!) delivered by college‐aged black mentors
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Health promotion/obesity prevention program (Challenge!)
Number of subjects: 235
Study: 17175075

Group type: EXPERIMENTAL
Intervention: Occlusion (jaw clenching)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No occlusion
Number of subjects: 30
Study: 15870629

Group type: EXPERIMENTAL
Intervention: NaHCO3 ingestion (0.2 g x kg(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: NaCl (placebo, 0.138 g x kg(‐1))
Number of subjects: 7
Study: 12049015

Group type: EXPERIMENTAL
Intervention: Epidural Ropivacain (R) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural Bupivacain (B) infusion
Number of subjects: 20
Study: 10613613

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (80 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chloroguanide (200 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dextromethorphan and Chloroguanide (combined)
Number of subjects: 36
Study: 7778068

Group type: EXPERIMENTAL
Intervention: 30 mg subcutaneous
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 mg subcutaneous
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 mg intravenous
Number of subjects: 12
Study: 2140250

Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 micrograms/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study: 6999545

Group type: EXPERIMENTAL
Intervention: Naproxen tablets
Number of subjects: 32

Group type: COMPARATOR
Intervention: Naproxen suppositories
Number of subjects: 32
Study: 31373162

Group type: EXPERIMENTAL
Intervention: Hydration protocols (GA, GB, GC, GD, GE)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Dehydration (GF)
Number of subjects: 195
Study: 31565913

Group type: EXPERIMENTAL
Intervention: HICT modified‐ FIFA 11+ exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard FIFA 11+
Number of subjects: 39
Study: 27940648

Group type: EXPERIMENTAL
Intervention: Solitaire thrombectomy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 206
Study: 26495289

Group type: EXPERIMENTAL
Intervention: Supreme LMA
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: ProSeal LMA
Number of subjects: 505

Group type: COMPARATOR
Intervention: Laryngeal Tube Suction-D
Number of subjects: 505

Group type: COMPARATOR
Intervention: SLIPA
Number of subjects: 505
Study: 23433601

Group type: EXPERIMENTAL
Intervention: LX4211 + sitagliptin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LX4211
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 18
Study: 21375606

Group type: EXPERIMENTAL
Intervention: Five-grass pollen sublingual immunotherapy tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19685003

Group type: EXPERIMENTAL
Intervention: Ecabet sodium (ES)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17709354

Group type: EXPERIMENTAL
Intervention: Group A received routine postoperative advice and a three-day prescription of paracetamol, ibuprofen, and codeine.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Group B used the Wong-Baker Faces Pain Scale.
Number of subjects: 88
Study: 15042276

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 11979408

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval appendectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complicated appendicitis treatment
Number of subjects: 0
Study: 9657576

Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 microg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8109489

Group type: EXPERIMENTAL
Intervention: Corticosteroid pretreatment (32-mg oral dose of methylprednisolone administered 6-24 hr before and again 2 hr before injection)
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Placebo (administered in the same time periods)
Number of subjects: 1155
Study: 2764287

Group type: EXPERIMENTAL
Intervention: Lumbar epidural anesthesia without hemodilution (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution without epidural anesthesia (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution during lumbar epidural anesthesia (Group 3)
Number of subjects: 30
Study: 1095631

Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride (300 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride
Number of subjects: 10
Study: 31556542

Group type: EXPERIMENTAL
Intervention: Multimodal biofeedback training involving cycling augmented by functional electrical stimulation (FES) and balance exercises (15 sessions of FES-cycling training followed by 15 sessions of balance training, 20 minutes each) in addition to usual care (70 minutes)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (30 sessions, 90 minutes)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Multimodal biofeedback training
Number of subjects: 68
Study: 31234848

Group type: EXPERIMENTAL
Intervention: UK Patient Activation Measure (PAM-13)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Think aloud interviews with PAM-13
Number of subjects: 57
Study: 29016336

Group type: EXPERIMENTAL
Intervention: Mebendazole (MBZ) 500 mg chewable tablet
Number of subjects: 295
Study: 25659194

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 968
Study: 24377409

Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy (average of 97 sessions, range: 25-205)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait-list control group (minimal treatment)
Number of subjects: 35
Study: 22249412

Group type: EXPERIMENTAL
Intervention: Self Measured Blood Pressure (SMBP)
Number of subjects: 57
Study: 19568355

Group type: EXPERIMENTAL
Intervention: 4 mg triamcinolone acetonide
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 8 mg triamcinolone acetonide
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 25 mg triamcinolone acetonide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 44
Study: 17475891

Group type: EXPERIMENTAL
Intervention: Recombinant gp120 vaccination
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 530
Study: 15755868

Group type: EXPERIMENTAL
Intervention: HRT-EVP (sequential estradiol valerate plus progestin)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: HRT-EV (estradiol valerate alone)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 88
Study: 12062464

Group type: EXPERIMENTAL
Intervention: LAAM (levo‐alpha‐acetylmethadol)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 62
Study: 10656038

Group type: EXPERIMENTAL
Intervention: 800 mg oral penicillin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1 mg DEC/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 800 mg oral penicillin plus 1 mg DEC/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: local antibiotics
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study: 8521712

Group type: EXPERIMENTAL
Intervention: Continuous levonorgestrel treatment with subdermal implants (Norplant)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Depot‐medroxyprogesterone acetate (DMPA)
Number of subjects: 22
Study: 2245269

Group type: EXPERIMENTAL
Intervention: Treatment during the Sheffield Psychotherapy Project
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prescriptive therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exploratory therapies
Number of subjects: 40
Study: 493227

Group type: EXPERIMENTAL
Intervention: Neuroleptic anaesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General anaesthesia with halothane
Number of subjects: 0
Study: 29696832

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (100 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 27356530

Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg soft gelatin capsule (marketed formulation)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg hard gelatin capsule
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg soft gelatin capsules with 300 mg MDC8
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg soft gelatin capsules with 100 mg MDC8
Number of subjects: 73
Study: 24796660

Group type: EXPERIMENTAL
Intervention: Signs of Suicide (SOS) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22710616

Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthcare professional-led asthma program
Number of subjects: 91
Study: 20092962

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radiotherapy (CRT)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 218
Study: 18402657

Group type: EXPERIMENTAL
Intervention: Brief personalized normative feedback intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (measurement effects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (intervention effects)
Number of subjects: 0
Study: 15837357

Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol (50mg/kg/day in four divided doses for 14 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ofloxacin (15 mg/kg/day in two divided doses for 3 days)
Number of subjects: 50
Study: 12028688

Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Dipyridamole (750 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and dipyridamole
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 10477984

Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ketac-Bond
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 8708763

Group type: EXPERIMENTAL
Intervention: Perfusion lung scans with 1-3 small subsegmental defects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion lung scans with > 3 small subsegmental defects
Number of subjects: 0
Study: 1918724

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1.2 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 2.4 mg per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Morning dosing schedule
Number of subjects: 40
Study: 6578646

Group type: EXPERIMENTAL
Intervention: Sputum samples collected from the 1st to 26th postinfarction days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Specific cytologic features observed
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Comparison to canine model
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Case presentation
Number of subjects: 9